←
Vun-Sin Lim, PhD1,373 posts
Vun-Sin Lim, PhD avatar

Vun-Sin Lim, PhD

@vs_lim

Managing Editor of the Journal of Thoracic Oncology | Tweets are my own | Bluesky handle: bsky.app/profile/vslim.bsky.…

◷ Joined October 2013▧ 73 Photos and videos
Dr Riyaz Shah avatar
⟳ Vun-Sin Lim, PhD retweeted
Dr Riyaz Shah@DrRiyazShah·Nov 16

Lovely analysis in Her2 mutated NSCLC demonstrating that in the absence of H2H data, on balance the TKI's have it. ADC activity maintained post TKI. TKI good in YVMA + active in non-TKD mutations. This is a very exciting space with lots happening. @IASLC jto.org/article/S1556-0864(2…

Hidehito HORINOUCHI avatar
⟳ Vun-Sin Lim, PhD retweeted
Hidehito HORINOUCHI@HHorinouchi·Nov 15

🔥PECATI final analysis: lenvatinib + pembrolizumab in pretreated B3 thymoma & thymic carcinoma 🆙 @JTOonline ☑Phase 2; N=43 (84% TC); mFU 24.6 mo 🎯mPFS 22.1 mo, mOS 40.2 mo; 36-mo OS 53.0%; ORR 25.6% 🎯Grade ≥3 TRAEs 44.2% (discontinuation 27.9%); grade 3 irAEs 11.6% 🎙 @JordiRemon @nicogirardcurie @NReguart @BenjaminBesseMD #LCSM @OncoAlert @Larvol jto.org/article/S1556-0864(2…

What’s next for patients with platinum-refractory advanced B3 thymoma and thymic carcinoma? With no standard second-line treatment, new research is critical. Remon et al. share updated findings from the PECATI trial, now published in #JTO. Read more: bit.ly/3Xqcqra

Post attachment
JTO & JTO CRR avatar
⟳ Vun-Sin Lim, PhD retweeted
JTO & JTO CRR@JTOonline·Nov 16

Celebrating a leader who has helped support scientific discovery and knowledge sharing for nine years. Thank you, Johan Vansteenkiste! #JTO20

Post attachment
JTO & JTO CRR avatar
⟳ Vun-Sin Lim, PhD retweeted
JTO & JTO CRR@JTOonline·Nov 16

As we reflect on two decades of JTO, we're grateful for contributors like Ramon Rami-Porta, whose seven years of service have left a lasting mark. #JTO20

Post attachment
Jordi Remon avatar
⟳ Vun-Sin Lim, PhD retweeted
Jordi Remon@JordiRemon·Nov 14

📓 Final PECATI trial supports PEMBRO + LENVATINIB in pretreated met B3 thymoma & thymic Ca. 📊 mINV-PFS: 22 mo | OS: 40 mo 🚀 Can IO, ADCs & bispecifics move to 1st line? 💪🏻 More academic & pharma collaboration is needed in rare thoracic malignancies! 🔗 authors.elsevier.com/a/1o6FL…

Post attachment
JTO & JTO CRR avatar
⟳ Vun-Sin Lim, PhD retweeted
JTO & JTO CRR@JTOonline·Nov 13

#LDCT lung cancer screening has been an approved covered benefit for adults aged 55-77 years by the Centers for Medicare and Medicaid Services since 2015. Miller et al. sought to compare the cancer detection rates in a general population #lungcancer screening registry to the #NLST, which they found were comparable. Read the article here: bit.ly/4sObSaB #LungCancerResearch #JTO

Post attachment
Stephen V Liu, MD avatar
⟳ Vun-Sin Lim, PhD retweeted
Stephen V Liu, MD@StephenVLiu·Nov 12

Determinants of early progression on 1L osimertinib in EGFR-mutant NSCLC @JTOonline. Baseline TP53 mutation and PD-L1 associated with early progression as were mutations in various tumor suppressor genes (RBM10, CREBBP, ATM, RB1, KMT2D, TSC2, PTEN). jto.org/article/S1556-0864(2…

JTO & JTO CRR avatar
⟳ Vun-Sin Lim, PhD retweeted
JTO & JTO CRR@JTOonline·Nov 12

@KalantriShreyas et al. sought to characterize real-world uptake of immunotherapy as standard first-line therapy for NSCLC patients with advanced disease and without actionable driver alterations. They found that race and ethnicity, insurance status, age, and comorbidity are suggested factors in the ongoing inequities in real-world delivery of this treatment. Read more on their findings here: bit.ly/4sYktHK #LungCancerResearch #LungCancer #NSCLC @uofcincycancer | @UCResearch | @uofcincy | @uofl | @UofLBCC

Post attachment
JTO & JTO CRR avatar
⟳ Vun-Sin Lim, PhD retweeted
JTO & JTO CRR@JTOonline·Nov 11

📊 JTO Fun Fact Looking for the latest on TNM staging? JTO curates IASLC Staging Articles, including proposals for the Ninth Edition of TNM Stage Classification of Thoracic Tumors. Access the collection: bit.ly/4gwWMlg #JTO20 #GlobalOncology

Post attachment
JTO & JTO CRR avatar
⟳ Vun-Sin Lim, PhD retweeted
JTO & JTO CRR@JTOonline·Nov 10

Join us in recognizing Tetsuya Mitsudomi for nine years of service and his contributions to JTO's continued success! #JTO20

Post attachment
Stephen V Liu, MD avatar
⟳ Vun-Sin Lim, PhD retweeted
Stephen V Liu, MD@StephenVLiu·Nov 9

Phase II results for soxataltinib, CNS penetrant selective RET inhibitor, in NSCLC @JTOonline. As 1L therapy, RR 89.3%, TTR 0.9m, PFS 19.3m, intracranial RR 100% (n=4) and TRAEs included AST elevation (71%, G3+ 9%) and notably, diarrhea (79%, G3+ 18%). jto.org/article/S1556-0864(2…

JTO & JTO CRR avatar
⟳ Vun-Sin Lim, PhD retweeted
JTO & JTO CRR@JTOonline·Nov 9

Amid ongoing debate about the optimal technical strategy of performing ctDNA-based assays to detect minimal residual disease after surgery, Cui et al. put the methods to the test. In 417 plasma samples from 84 patients with stages I-III LC, they found that personalized tumor-informed assays provided the best prediction for disease recurrence. Dive into the details here: bit.ly/4swRBpR #ctDNA #LungCancer #LungCancerResearch #JTO

Post attachment
JTO & JTO CRR avatar
⟳ Vun-Sin Lim, PhD retweeted
JTO & JTO CRR@JTOonline·Nov 8

Thank you to Graham Warren for ten years of helping JTO serve as a trusted resource for the global thoracic oncology community! #JTO20

Post attachment